Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nippon Kayaku Grabs Japan Rights to Lilly’s Soon-to-Launch Portrazza
Nippon Kayaku said on April 22 that it has been granted exclusive rights in Japan to manufacture and commercialize Eli Lilly’s soon-to-be-approved lung cancer treatment necitumumab, an EGFR antagonist also known as Portrazza overseas. Necitumumab is a recombinant human IgG1…
To read the full story
Related Article
- Nippon Kayaku Skips September Listing for Lilly’s Portrazza
August 29, 2019
BUSINESS
- Santen Snags China Rights to 5 Glaucoma Drugs from AbbVie
April 20, 2026
- AbbVie Launches Aquipta Migraine Drug in Japan
April 20, 2026
- Fronteo, Astellas Partner on AI-Driven Drug Target Discovery
April 20, 2026
- Towa to Outsource 1.5 Billion Tablets to Adragos by 2033
April 20, 2026
- Lilly’s Omvoh 200 mg SC Wins Japan Nod for UC Maintenance Use
April 17, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…